Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ENOV 
Enovis Corp (ENOV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: ENOV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $49.67
1 Year Target Price $49.67
| 7 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.32% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.62B USD | Price to earnings Ratio - | 1Y Target Price 49.67 |
Price to earnings Ratio - | 1Y Target Price 49.67 | ||
Volume (30-day avg) 11 | Beta 1.65 | 52 Weeks Range 25.47 - 49.75 | Updated Date 11/7/2025 |
52 Weeks Range 25.47 - 49.75 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When - | Estimate 0.6497 | Actual - |
Profitability
Profit Margin -37.8% | Operating Margin (TTM) 2.41% |
Management Effectiveness
Return on Assets (TTM) 0.89% | Return on Equity (TTM) -28.25% |
Valuation
Trailing PE - | Forward PE 8.64 | Enterprise Value 3166929981 | Price to Sales(TTM) 0.74 |
Enterprise Value 3166929981 | Price to Sales(TTM) 0.74 | ||
Enterprise Value to Revenue 1.45 | Enterprise Value to EBITDA 22.42 | Shares Outstanding 57159803 | Shares Floating 56419584 |
Shares Outstanding 57159803 | Shares Floating 56419584 | ||
Percent Insiders 1.57 | Percent Institutions 119.99 |
Upturn AI SWOT
Enovis Corp
Company Overview
History and Background
Enovis Corp, formerly known as Colfax Corporation, underwent a significant transformation and rebranding. Initially founded in 1995 by Steven and Mitchell Rales, it evolved from a diversified industrial manufacturer to a focused medical technology company.
Core Business Areas
- Reconstructive: This segment includes products and services for joint reconstruction, sports medicine, and fracture management. It focuses on surgical solutions, implants, and related technologies.
- Prevention & Recovery: This segment provides bracing, support, and rehabilitation products for injury prevention, pain management, and post-operative recovery. It includes products like orthopedic braces, compression garments, and rehabilitation equipment.
Leadership and Structure
Matt Trerotola serves as the Chief Executive Officer. The company is structured with a board of directors and executive leadership team overseeing various functional areas and business segments.
Top Products and Market Share
Key Offerings
- DJO Surgical: DJO Surgical offers reconstructive joint solutions, including hip, knee, and shoulder implants. It has estimated market share of 5-8% in the global orthopedic implant market. Competitors include Stryker (SYK), Zimmer Biomet (ZBH), and Johnson & Johnson (JNJ).
- DJO Bracing and Vascular: This product line offers bracing and vascular therapy solutions. Estimated market share of 20-25% in the global bracing and support market. Competitors include BSN medical (owned by Essity), Bauerfeind, and u00d6ssur.
Market Dynamics
Industry Overview
The medical technology industry is characterized by innovation, regulatory scrutiny, and an aging global population driving demand for orthopedic and rehabilitation solutions. Growth is also fueled by increasing sports-related injuries and advancements in minimally invasive procedures.
Positioning
Enovis Corp is positioned as a leading provider of reconstructive and rehabilitation solutions. Its competitive advantages lie in its diversified product portfolio, established brand reputation, and focus on innovation.
Total Addressable Market (TAM)
The global orthopedic market is estimated at over $50 billion. Enovis is targeting portions of this TAM including the sports medicine market, which is around $8 billion, and fracture management market.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Established brand reputation (DJO)
- Focus on innovation and technology
- Global sales and distribution network
- Strong presence in bracing and support market
Weaknesses
- Exposure to regulatory risks
- Dependence on hospital spending
- Integration risks from acquisitions
- Competition from larger players
- Debt from prior acquisitions
Opportunities
- Expanding product offerings
- Growth in emerging markets
- Technological advancements in orthopedics
- Acquisitions of complementary businesses
- Increase in minimally invasive surgeries
Threats
- Economic downturns impacting hospital budgets
- Increased price competition
- Changes in reimbursement policies
- Product liability claims
- Technological obsolescence
Competitors and Market Share
Key Competitors
- STRYKER (SYK)
- ZIMMER BIOMET (ZBH)
- JOHNSON & JOHNSON (JNJ)
- SMITH & NEPHEW (SNN)
Competitive Landscape
Enovis Corp is smaller than its main competitors, such as Stryker and Zimmer Biomet. Enovis's strength lies in its bracing and support products, while Stryker and Zimmer Biomet have a larger presence in reconstructive joint solutions.
Major Acquisitions
Insightra Medical
- Year: 2024
- Acquisition Price (USD millions): 48
- Strategic Rationale: Insightra Medical allows Enovis to expand its extremities orthopedic solutions, specifically in foot and ankle. Adding solutions to accelerate future growth.
Growth Trajectory and Initiatives
Historical Growth: Data to be included here once available
Future Projections: Data to be included here once available
Recent Initiatives: Recent Initiatives include cost management initiatives, expansion into new markets and product lines, and focusing on technology and innovation.
Summary
Enovis is a focused medical technology company undergoing a transformation. Its strengths include a diversified product portfolio and established brand in bracing and support, but faces competition from larger players. Focus on innovation and strategic acquisitions is critical to future growth, which the recent Insightra acquisition helps support. The company needs to manage regulatory risks and economic sensitivities well.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
- Third party sources
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enovis Corp
Exchange NYSE | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2008-05-08 | CEO & Director Mr. Damien McDonald | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7367 | Website https://www.enovis.com |
Full time employees 7367 | Website https://www.enovis.com | ||
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.